Jamie L Fraser1, Charles P Venditti. 1. aDivision of Genetics and Metabolism, Children's National Medical Center, Washington, District of Columbia bMedical Genomics and Metabolic Genetics Branch, National Human Genome Research Institute, National Institutes of Health, Bethesda, Maryland, USA.
Abstract
PURPOSE OF REVIEW: Recent clinical studies and management guidelines for the treatment of the organic acidopathies methylmalonic acidemia (MMA) and propionic acidemia address the scope of interventions to maximize health and quality of life. Unfortunately, these disorders continue to cause significant morbidity and mortality due to acute and chronic systemic and end-organ injury. RECENT FINDINGS: Dietary management with medical foods has been a mainstay of therapy for decades, yet well controlled patients can manifest growth, development, cardiac, ophthalmological, renal, and neurological complications. Patients with organic acidopathies suffer metabolic brain injury that targets specific regions of the basal ganglia in a distinctive pattern, and these injuries may occur even with optimal management during metabolic stress. Liver transplantation has improved quality of life and metabolic stability, yet transplantation in this population does not entirely prevent brain injury or the development of optic neuropathy and cardiac disease. SUMMARY: Management guidelines should identify necessary screening for patients with methylmalonic acidemia and propionic acidemia, and improve anticipatory management of progressive end-organ disease. Liver transplantation improves overall metabolic control, but injury to nonregenerative tissues may not be mitigated. Continued use of medical foods in these patients requires prospective studies to demonstrate evidence of benefit in a controlled manner.
PURPOSE OF REVIEW: Recent clinical studies and management guidelines for the treatment of the organic acidopathies methylmalonic acidemia (MMA) and propionic acidemia address the scope of interventions to maximize health and quality of life. Unfortunately, these disorders continue to cause significant morbidity and mortality due to acute and chronic systemic and end-organ injury. RECENT FINDINGS: Dietary management with medical foods has been a mainstay of therapy for decades, yet well controlled patients can manifest growth, development, cardiac, ophthalmological, renal, and neurological complications. Patients with organic acidopathies suffer metabolic brain injury that targets specific regions of the basal ganglia in a distinctive pattern, and these injuries may occur even with optimal management during metabolic stress. Liver transplantation has improved quality of life and metabolic stability, yet transplantation in this population does not entirely prevent brain injury or the development of optic neuropathy and cardiac disease. SUMMARY: Management guidelines should identify necessary screening for patients with methylmalonic acidemia and propionic acidemia, and improve anticipatory management of progressive end-organ disease. Liver transplantation improves overall metabolic control, but injury to nonregenerative tissues may not be mitigated. Continued use of medical foods in these patients requires prospective studies to demonstrate evidence of benefit in a controlled manner.
Authors: A M Lamhonwah; T J Barankiewicz; H F Willard; D J Mahuran; F Quan; R A Gravel Journal: Proc Natl Acad Sci U S A Date: 1986-07 Impact factor: 11.205
Authors: Martin Kömhoff; Marcus T Roofthooft; Dineke Westra; Thea K Teertstra; Attilio Losito; Nicole C A J van de Kar; Rolf M F Berger Journal: Pediatrics Date: 2013-07-08 Impact factor: 7.124
Authors: Liise K Kayler; Robert M Merion; Samuel Lee; Randall S Sung; Jeffrey D Punch; Steven M Rudich; Jeremiah G Turcotte; Darrell A Campbell; Ronald Holmes; John C Magee Journal: Pediatr Transplant Date: 2002-08
Authors: R Lubrano; E Bellelli; I Gentile; S Paoli; C Carducci; C Carducci; S Santagata; B Pérez; M Ugarte; D Labriola; M Elli Journal: Am J Transplant Date: 2013-05-24 Impact factor: 8.086
Authors: S B van der Meer; F Poggi; M Spada; J P Bonnefont; H Ogier; P Hubert; E Depondt; D Rapoport; D Rabier; C Charpentier Journal: J Pediatr Date: 1994-12 Impact factor: 4.406
Authors: M Dercksen; L IJlst; M Duran; L J Mienie; A van Cruchten; F H van der Westhuizen; R J A Wanders Journal: Biochim Biophys Acta Date: 2013-05-02
Authors: Irini Manoli; Justin R Sysol; Madeline W Epping; Lina Li; Cindy Wang; Jennifer L Sloan; Alexandra Pass; Jack Gagné; Yiouli P Ktena; Lingli Li; Niraj S Trivedi; Bazoumana Ouattara; Patricia M Zerfas; Victoria Hoffmann; Mones Abu-Asab; Maria G Tsokos; David E Kleiner; Caterina Garone; Kristina Cusmano-Ozog; Gregory M Enns; Hilary J Vernon; Hans C Andersson; Stephanie Grunewald; Abdel G Elkahloun; Christiane L Girard; Jurgen Schnermann; Salvatore DiMauro; Eva Andres-Mateos; Luk H Vandenberghe; Randy J Chandler; Charles P Venditti Journal: JCI Insight Date: 2018-12-06
Authors: Nishitha R Pillai; Bridget M Stroup; Anna Poliner; Linda Rossetti; Brandy Rawls; Brian J Shayota; Claudia Soler-Alfonso; Hari Priya Tunuguntala; John Goss; William Craigen; Fernando Scaglia; V Reid Sutton; Ryan Wallace Himes; Lindsay C Burrage Journal: Mol Genet Metab Date: 2019-11-07 Impact factor: 4.797
Authors: Allison J Armstrong; Maria Sol Collado; Brad R Henke; Matthew W Olson; Stephen A Hoang; Christin A Hamilton; Taylor D Pourtaheri; Kimberly A Chapman; Marshall M Summar; Brian A Johns; Brian R Wamhoff; John E Reardon; Robert A Figler Journal: Mol Genet Metab Date: 2021-03-10 Impact factor: 4.204
Authors: Randy J Chandler; Leah E Venturoni; Jing Liao; Brandon T Hubbard; Jessica L Schneller; Victoria Hoffmann; Susana Gordo; Shengwen Zang; Chih-Wei Ko; Nelson Chau; Kyle Chiang; Mark A Kay; Adi Barzel; Charles P Venditti Journal: Hepatology Date: 2021-05-21 Impact factor: 17.298